Elizabeth Fox, MD

Elizabeth Fox, MD, is an attending physician and head of Developmental Therapeutics at CHOP’s Cancer Center. She has specific expertise in neuro-endocrine tumors.

Areas of Expertise: Neuro-endocrine tumors
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Education and Training

    Medical School

    MD - Pennsylvania State University College of Medicine, Hershey, PA

    Internship

    Pediatrics - Strong Memorial Hospital, University of Rochester, Rochester, NY

    Residency

    Pediatrics - Strong Memorial Hospital, University of Rochester, Rochester, NY

    Fellowship

    Pediatric Hematology/ Oncology - Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

    Board Certification

    Pediatric Hematology-Oncology

    Graduate Degree

    MS in Clinical Research - Duke University College of Medicine, Durham, NC

  • Titles and Academic Titles

    Attending Physician

    Head, Developmental Therapeutics, Division of Oncology

    Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Departments and Services
  • Publications

    Books

    Chapters

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. 2nd ed. Burlington: Academic Press; 2006.

    Fox E, Adamson PC. Future trends in cancer chemotherapy. In: Voute PA, Barrett A, Stevens, MCG, editors. Cancer in children clinical management. 5th ed. New York: Oxford University Press; 2005.

    Fox E, Adamson PC. Phase I trial design considerations in the pediatric population. In: Budman DR, Calvert AH, Rowinsky EK, editors. Handbook of anticancer drug development. Philadelphia: Lippincott Williams & Wilkins; 2003.

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2003.

    Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2001.

    Abstracts

    2015

    Akshintala S, Dombi E, Glod J, Fox E, Lodish M, Whitcomb P, Balis FM, Widemann BC.  Response and Resistance to the Receptor Tyrosine Kinase Inhibitor Vandetanib in Pediatric Patients with Medullary Thyroid Carcinoma.  American Society of Pediatric Hematology Oncology; Phoenix, AZ, 2015.

    Fox E, Amodei K, Mattei P, Kolon T, Johnson A, Darge C, Balis FM.  Longitudinal assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors. Cancer and the Kidney (c-kin) International, Brussels, Belgium, 2015.

    2014

    London LB, Bagatell R, Weigel B, Fox E, Van Ryn C, Naranjo A, Krailo MD, Ahern CH, Park JR; Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients. American Society of Clinical Oncology, Chicago, IL, 2014.

    Fox E, Amodei K, Mattei P, Kolon T, Johnson A, Darge C, Balis FM.  Prospective assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors American Society of Clinical Oncology, Chicago, 2014.

    Meany HJ, Hinds PS, Bagatell R, Shusterman S, Widemann BC, Stern E, London WB, Kim A, Fox E, Rodriguez-Galindo C, Minturn JE, Dome J. Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors. American Society of Clinical Oncology, Chicago, IL, 2014.

    Chuk M, Widemann B, Ahern C, Reid J, Fox E, Weigel B, Blaney SM. Cabozantinib, an oral inhibitor of tyrosine kinases including MET, VEGFR2 and RET, is approved for adults with progressive, metastatic medullary thyroid carcinoma (MTC).  We conducted a phase I and pharmacokinetic (PK) trial of cabozantinib in children with refractory solid tumors. American Society of Clinical Oncology, Chicago, IL, 2014.

    Geller J,  Perentesis J, Ahern CH, Kudgus RA, Reid JM, Fox E,  Blaney M, Weigel BJ.  A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. American Society of Clinical Oncology, Chicago, IL, 2014.

    DuBois SG, Mosse YP, Fox E, Reid J, Groshen S, Tsao-Wei D, Bagatell R, Maris J, Wagner L, Marachelian A, Matthay K. Phase I Study of the Aurora A Kinase Inhibitor MLN8237 with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma:  A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium Advance in Neuroblastoma Cologne, Germany, 2014.

    2013

    Akshintala S, Jones E,  Dombi E,  Fox E, Lodish M, Whitcomb P,  Balis FM,  Widemann B.  Characteristics of pediatric patients with advanced medullary thyroid carcinoma associated with multiple endocrine neoplasia 2B due to RET M918T mutation.  American Society of Pediatric Hematology Oncology; Miami, FL, 2013.

    Lodish MB, Bornstein E, Sinali N, Fox E, Chuk M, Marcus L, Srivandana A, Whitcomb PO, Akin A, Balis FM, Widemann BC, Stratakis CA.  Patterns of Thyroid Hormone Levels in Athyrotic Pediatric Medullary Thyroid Carcinoma Patients on Vandetanib Therapy ENDO2013 San Francisco, CA, 2013. 

    Papers

    2015

    Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weige BJ,  Blaney SM,  Phase 2 trial of Sorafenib in Children and Young Adults with Refractory Solid Tumors: A Report from the Children’s Oncology Group Ped Blood Cancer in press (2015)

    Lodish MB, Gkourogianni A, Bornstein E, Sinaii N, Fox E, Chuk M, Marcus L, Akshintala S, Balis F, Widemann B, and Stratakis CA. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.  International Journal of Pediatric Endocrinology (2015) in press.

    2014

    Norris R, Moorthy G, Adamson PC, Fox E.  A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma J Chromatogr B Analyt Technol Biomed Life Sci. 15;971:30-4, 2014.

    Desai A, Fox E, Smith LM, Lim AP, Maris JM, Balis FM.  Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high risk neuroblastoma. Cancer Chemotherap Pharmacol (2014) 74(5):1047-55, 2014.

    Himebauch AS, Nicolson SA, Sisko M, Moorthy G, Fuller S, Gaynor JW, Zuppa A, Fox E, Kilbaugh T.  Skeletal Muscle and Plasma Concentrations of Cefazolin during Cardiac Surgery in Infants J Thoracic Cardiovascular Surgery 148(6):2634-41,  2014.

    Norris R, Shusterman S, Gore L, Muscal J, Macy M, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children, adolescents, and young adults with relapsed or refractory solid tumors.  Pediatric Blood and Cancer 61:17922-1797, 2014.

    Widemann BC, Babovic-Vuksanovic D., Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A., Goodspeed, W, Kieran, MW, Cohen B., Blaney SM., King A., Solomon J., Patronas N., Balis, FM., Fox, E, Steinberg SM., Packer RJ.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.  Pediatric Blood and Cancer 61(9) 1598-602, 2014

    Widemann BC, Dombi E, Gilespie A, Wolters P, Belasco J, Goldman S, Korf B, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran M, Perentesis J, Reddy A, Wright J, Kim A, Steinberg S, Balis FM.  Phase II randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas Neuro Oncol. May;16(5):707-18, 2014.

    Fox E, Mosse YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn CL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621) Pediatric Blood and Cancer 61(6) 990-6, 2014.

    Bagatell R, Norris R, Ingle AM, Ahern CH, Voss S, Fox E, Little A, Weigel B, PA Adamson PA, Blaney SM Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors:  A Children’s Oncology Group Study. Pediatr Blood Cancer. May;61(5):833-9, 2014.

    Norris R, Adamson PC, Nguyen VT, Fox E. Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination with Cytotoxic Chemotherapy in Pediatric Solid Tumors. Ped Blood Cancer Jan;61(1):145-50, 2014 .

    2013

    Fox E, Widemann BC, Chuk MK, Marcus LM, Aikin A, Whitcomb PO, Merino MJ, Lodish M,  Dombi E, Steinberg S,  Wells SA, Balis FM. Vandetanib  in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.  Clin Cancer Res 19(15) 4239-48, 2013.

    Posters and Presentations

    Invited Lectures

    2015

    Seminar: Updates in Pediatric Oncology: Skin Cancer Not So Fun in The Sun

    2014

    Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, MA Invited Lecture: The Role of Pharmacology in Clinical Drug Development in Oncology

    Visiting Faculty, Pediatric Oncology and Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, MN: Role of Clinical Pharmacology in Pediatric Oncology Drug Development

    Visiting Professor, Introduction to Principles of Pharmacokinetics Course (T32 and Graduate Program Clinical Pharmacology), Mayo Clinic, Rochester, MN:  Drug Distribution and Pharmacokinetics in Pediatrics

    2013

    Visiting Professor, Children’s Mercy Medical Center, Clinical Pharmacology and Pediatric Hematology/Oncology:  Pharmacology of Central Nervous System Directed Therapy

    Center For Childhood Research Seminar Series, Children’s Hospital of Philadelphia Research Institute: Development of targeted agents in children with rare tumors.

  • Awards and Honors

    2008, NIH Award of Merit for the Transition of Carboxypeptidase Treatment Program (group award)
    2006, NIH Director’s Award of Merit for Contributions to Clinical Development of Treatment for Childhood Cancer (individual award)
    2002, ASCO Merit Award
    2000, AACR- Glaxo Wellcome Oncology Scholar Award for Promising Clinical/Translational Research
    1999, NCI Fellowship Training Award
    1995, Feigin Scholar, Texas Children’s Hospital
    1991, Shapiro Scholar, Dept. Pediatrics, University of Rochester

  • Editorial and Academic Positions

    Editorial positions

    Editorial boards

    2007-present, Associate Editor, Journal of the National Cancer Institute

    Scientific reviewer

    Blood
    Cancer Chemotherapy & Pharmacology
    Cancer Research
    Clinical Cancer Research
    Journal of Clinical Oncology
    Journal of the National Cancer Institute
    Journal of Pediatric Hematology & Oncology
    Journal of Pharmacology & Experimental Therapeutics
    Pediatric Blood & Cancer

    Academic positions

    2008-present, NCI Seminar Series Organizational Committee, Pediatric Oncology Branch

    2008-present, Children's Oncology Group Neuroblastoma Committee, Task Force for Study Design of Maintenance Therapy for High Risk Neuroblastoma

    2008-present, Biomedical Research Information System Development Task Force Center for Cancer Research, NCI

    2007-present, Pediatric Oncology Branch, NCI Web Development Committee

    2006-present, Children's Oncology Group Neuroblastoma Committee

    2006-present, Children's Oncology Group Trial Design and Endpoints in Neuroblastoma Task Force

    2004-present, Center for Cancer Research Early Drug Development Committee

    Children's Oncology Group Study Committees

    • ADVL1021 Phase 2 Study of Cediranib in Children With Refractory Solid Tumors
    • ADVL0811 Phase I Study of AZ2281, Oral PARP Inhibitor in Combination With Temozolomide or Irinotecan
    • ADVL0721 Phase 2 Trial of ABT-751 in Children With Ewings Sarcoma, Osteosarcoma, Rhabdomyosarcoma, or Wilms Tumor
    • ANBL0621 Phase 2 Trial of ABT-751 in Children With Refractory Neuroblastoma
    • ADVL0524 Phase 2 Trial of Ixabepilone in Children With Refractory Solid Tumors
    • ADVL0413 Phase I Study of Sorafenib in Children With Relapsed Solid Tumors

     

  • Leaderships

    Memberships in Professional Organizations

    2002-present, Children’s Oncology Group
    1998-present, American Society of Clinical Oncology
    1997-present, American Association for Cancer Research